789 related articles for article (PubMed ID: 19154450)
21. Treatment of chronic prostatitis lowers serum prostate specific antigen.
Bozeman CB; Carver BS; Eastham JA; Venable DD
J Urol; 2002 Apr; 167(4):1723-6. PubMed ID: 11912396
[TBL] [Abstract][Full Text] [Related]
22. [Testosterone substitution in patients with hypogonadism].
Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
[TBL] [Abstract][Full Text] [Related]
23. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate.
Mydlo JH; Tieng NL; Volpe MA; Chaiken R; Kral JG
Prostate Cancer Prostatic Dis; 2001; 4(2):101-105. PubMed ID: 12497046
[TBL] [Abstract][Full Text] [Related]
24. Relationship of erythrocyte membrane polyunsaturated fatty acids and prostate-specific antigen levels in Jamaican men.
Ritch CR; Brendler CB; Wan RL; Pickett KE; Sokoloff MH
BJU Int; 2004 Jun; 93(9):1211-5. PubMed ID: 15180607
[TBL] [Abstract][Full Text] [Related]
25. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
Kuller LH; Thomas A; Grandits G; Neaton JD;
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):373-7. PubMed ID: 15006911
[TBL] [Abstract][Full Text] [Related]
26. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):106-12. PubMed ID: 12028683
[TBL] [Abstract][Full Text] [Related]
28. Androgens and the ageing male.
Swerdloff RS; Wang C
Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):349-62. PubMed ID: 15261842
[TBL] [Abstract][Full Text] [Related]
29. Ejaculation increases the serum prostate-specific antigen concentration.
Tchetgen MB; Song JT; Strawderman M; Jacobsen SJ; Oesterling JE
Urology; 1996 Apr; 47(4):511-6. PubMed ID: 8638359
[TBL] [Abstract][Full Text] [Related]
30. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
31. What happens to testosterone after prostate radiation monotherapy and does it matter?
Pickles T; Graham P;
J Urol; 2002 Jun; 167(6):2448-52. PubMed ID: 11992055
[TBL] [Abstract][Full Text] [Related]
32. Association between prostate cancer and serum testosterone levels.
Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
[TBL] [Abstract][Full Text] [Related]
33. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
Jenkins DJ; Kendall CW; D'Costa MA; Jackson CJ; Vidgen E; Singer W; Silverman JA; Koumbridis G; Honey J; Rao AV; Fleshner N; Klotz L
J Urol; 2003 Feb; 169(2):507-11. PubMed ID: 12544298
[TBL] [Abstract][Full Text] [Related]
34. Temporal (circadian) and functional relationship between prostate-specific antigen and testosterone in healthy men.
Mermall H; Sothern RB; Kanabrocki EL; Quadri SF; Bremner FW; Nemchausky BA; Scheving LE
Urology; 1995 Jul; 46(1):45-53. PubMed ID: 7541585
[TBL] [Abstract][Full Text] [Related]
35. Prostatic complications of testosterone replacement therapy.
Jackson JA; Waxman J; Spiekerman AM
Arch Intern Med; 1989 Oct; 149(10):2365-6. PubMed ID: 2679476
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
37. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
Heaton JP
Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
[TBL] [Abstract][Full Text] [Related]
38. Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.
Egawa S; Okusa H; Matsumoto K; Suyama K; Baba S
Prostate Cancer Prostatic Dis; 2003; 6(3):245-9. PubMed ID: 12970730
[TBL] [Abstract][Full Text] [Related]
39. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.
Dockery F; Bulpitt CJ; Agarwal S; Donaldson M; Rajkumar C
Clin Sci (Lond); 2003 Feb; 104(2):195-201. PubMed ID: 12546642
[TBL] [Abstract][Full Text] [Related]
40. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
Johansen KL
Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
